I am writing to you today to describe a significant change that is occurring at Senseonics.

Senseonics has been concerned since the COVID 19 outbreak, not only about the health and safety of our employees, patients and world, but about the effect that this pandemic has had on our ability to deliver the Eversense® CGM system to our users. Because our sensor requires an in-clinic procedure, we have seen a reduction in access to clinics and sensor insertions following the pandemic. The pandemic’s impact on the global health system and financial markets has caused Senseonics to meaningfully alter our current business plan.

To ensure continuity of care for our existing customers, we are reducing commercialization expenditures to focus our resources solely on existing customers. This will mean stopping sales and marketing efforts to acquire new Eversense users in the US. No new patients or clinics will be initiated. Only people currently using Eversense and those whose sensor has shipped will be inserted, as insurance allows. In addition, the insertion and removal procedures will be required to be done by providers who are already certified. To confirm that your health care provider is certified, please email support@eversensediabetes.com.

We will continue to support our present users in the US and outside of the US through our Customer Care Support Lines. We continue to monitor the usage of the system and complete our obligations to the appropriate regulatory bodies and to the diabetes community.

The company remains committed to the development and submission to the FDA of the US Eversense® XL product (up to 180 days). We believe that this new sensor system will be a highly desired CGM product that will offer a markedly innovative product to people with diabetes.

This narrowed focus of serving our current users while advancing the Eversense next generation product will enable us to focus our resources. Regretfully, as a direct result of the reduction in expenditures required by the current environment and situation, reducing our workforce, including the majority of our US sales and clinical organization. As you can imagine, this was not an easy decision, but one we had to make in order to continue serving our existing customers while developing our next generation product.

We thank you - our loyal users - for your continued and unwavering support of Eversense and Senseonics. We are as committed as ever to the advancement of CGM and to the people we serve.

Thank you,

Tim Goodnow, PhD
President & CEO
Senseonics Incorporated